Publication date: Aug 01, 2024
To investigate the value of histopathological examination (HPE) and Xpert Mycobacterium tuberculosis bacilli/rifampicin (MTB/RIF) assay in diagnosis of cervical lymph node tuberculosis (LN TB) after coarse needle biopsy (CNB). We retrospectively analyzed 612 samples obtained from October 2017 to August 2023 from patients suspected cervical LN TB with surgically pathological, microbial culture confirmed, and clinically confirmed cervical lymph node enlargement who received ultrasound-guided CNB assisted by contrast-enhanced ultrasound (CEUS) at our hospital. All specimens were assessed by HPE and the Xpert (MTB/RIF) assay. We analyzed the results to determine the diagnostic value of HPE and Xpert (MTB/RIF) assay in samples taken after CEUS-assisted CNB of LN TB, and to evaluate the safety of CNB. Based on the comprehensive reference standard established in this study, 532 of 612 patients were diagnosed with cervical LN TB, of which 476 were CNB positive cases, the positive rate of diagnosis was 89. 5%。The sensitivity, specificity, positive predictive value, negative and predictive value of HPE were 80. 4%, 91. 2%, 98. 4%, 41. 2% respectively, while those of the Xpert MTB/RIF assay were 75. 7%, 98. 7%, 99. 7%, 38. 0% respectively. No postoperative complications were noted, and the Clavien-Dindo grade was 2. CEUS-assisted CNB has high diagnostic value and is safe for cervical LN TB. The sensitivity of HPE is slightly higher than that of Xpert (MTB/RIF) assay, and the specificity of Xpert (MTB/RIF) assay is higher than that of HPE, so Xpert (MTB/RIF) assay can correct the cervical lymph node tuberculosis with negative HPE.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Biopsy | Cervical |
| Mycobacterium | CEUS |
| October | Coarse needle biopsy |
| Tuberculosis | Lymph node |
| Tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Rifampicin |
| disease | MESH | postoperative complications |
| disease | MESH | Infectious Diseases |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | Lymph node tuberculosis |
| disease | MESH | extrapulmonary tuberculosis |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | suppuration |
| disease | MESH | ulcer |
| disease | MESH | cerebrovascular diseases |
| disease | MESH | abscesses |
| drug | DRUGBANK | Sulfur hexafluoride |
| drug | DRUGBANK | Trestolone |
| disease | MESH | bleeding |
| drug | DRUGBANK | Formaldehyde |
| disease | MESH | inflammation |
| disease | MESH | hyperplasia |
| disease | MESH | complications |
| disease | MESH | lymphadenitis |
| disease | MESH | cancer |
| disease | MESH | infection |
| disease | MESH | postoperative pain |
| disease | MESH | pleural effusion |
| disease | MESH | uncertainty |
| drug | DRUGBANK | Spinosad |
| drug | DRUGBANK | Gold |
| disease | MESH | edema |
| disease | MESH | lymph node metastasis |
| disease | MESH | papillary thyroid carcinoma |
| drug | DRUGBANK | Piroxicam |
| disease | MESH | Tuberculous meningitis |